Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000197260 | SCV000254226 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2015-01-21 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been published in the literature and is not present in population databases. In summary, this is a novel missense change with uncertain impact on protein function. It has been classified as a Variant of Uncertain Significance. This sequence change replaces leucine with proline at codon 3184 of the BRCA2 protein (p.Leu3184Pro). The leucine residue is moderately conserved and there is a moderate physicochemical difference between leucine and proline. |
Ambry Genetics | RCV000561685 | SCV000661334 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-01-12 | criteria provided, single submitter | clinical testing | The p.L3184P variant (also known as c.9551T>C), located in coding exon 25 of the BRCA2 gene, results from a T to C substitution at nucleotide position 9551. The leucine at codon 3184 is replaced by proline, an amino acid with similar properties. This variant was similar to wildtype in a homology-directed DNA repair (HDR) assay (Ambry internal data). This amino acid position is highly conserved in available vertebrate species. Internal structural analysis indicates that this variant may destabilize the local structure (Ambry internal data). Since supporting evidence is conflicting at this time, the clinical significance of this alteration remains unclear. |
Color Diagnostics, |
RCV000561685 | SCV000684071 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-04-02 | criteria provided, single submitter | clinical testing |